Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19
Daniele Focosi, Federica Novazzi, Angelo Genoni, Francesco Dentali, Daniela Dalla Gasperina, Andreina Baj, Fabrizio Maggi
Abstract
recovered in blood and nasopharyngeal swab samples (notably on day 17). Such a phenomenon has been reported in clinical trials (9,10). Further analysis is needed to distinguish genetic changes that occur in the primary viral population from apparent changes to clarify whether such escape mutants are enough to spread and persist in humans and how SARS-CoV-2 displays compartmentalized replication. Genomic surveillance for SARS-CoV-2 variants is encouraged for COVID-19 patients given mAbs as monotherapy or biotherapy.
Topics & Concepts
MutationCoronavirus disease 2019 (COVID-19)CoronavirusSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Spike ProteinVirology2019-20 coronavirus outbreakBiologySpike (software development)BetacoronavirusSars virusGeneticsMedicineGeneOutbreakDiseaseInfectious disease (medical specialty)Internal medicineManagementEconomicsSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing